Meridian Bioscience Inc. (VIVO): Price and Financial Metrics

VIVO POWR Grades

• Quality is the dimension where VIVO ranks best; there it ranks ahead of 95.28% of US stocks.
• The strongest trend for VIVO is in Value, which has been heading down over the past 178 days.
• VIVO ranks lowest in Growth; there it ranks in the 8th percentile.

VIVO Stock Summary

• VIVO's went public 30.79 years ago, making it older than 83.6% of listed US stocks we're tracking.
• VIVO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 17.36% of US stocks.
• With a year-over-year growth in debt of -49.48%, MERIDIAN BIOSCIENCE INC's debt growth rate surpasses just 5.69% of about US stocks.
• If you're looking for stocks that are quantitatively similar to MERIDIAN BIOSCIENCE INC, a group of peers worth examining would be LFUS, FOXF, ISPC, LMAT, and CFMS.
• Visit VIVO's SEC page to see the company's official filings. To visit the company's web site, go to www.meridianbioscience.com.

VIVO Valuation Summary

• VIVO's EV/EBIT ratio is 24.5; this is 181.61% higher than that of the median Healthcare stock.
• VIVO's price/sales ratio has moved up 2.4 over the prior 243 months.

Below are key valuation metrics over time for VIVO.

VIVO Growth Metrics

The 2 year revenue growth rate now stands at 66.31%.
• Its 3 year cash and equivalents growth rate is now at 13.99%.
• Its year over year net income to common stockholders growth rate is now at -28.32%.

VIVO's revenue has moved up $147,816,000 over the prior 67 months.

The table below shows VIVO's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-06-30	343.547	94.853	43.411
2022-03-31	339.287	91.346	62.418
2021-12-31	313.32	77.299	59.968
2021-09-30	317.896	66.865	71.407
2021-06-30	305.845	68.682	71.243
2021-03-31	327.131	73.752	87.081

VIVO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• VIVO has a Quality Grade of B, ranking ahead of 84.82% of graded US stocks.
• VIVO's asset turnover comes in at 0.713 -- ranking 41st of 682 Pharmaceutical Products stocks.
• CPRX, CHRS, and XTNT are the stocks whose asset turnover ratios are most correlated with VIVO.

The table below shows VIVO's key quality metrics over time.